Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics.
Price History & Performance
|Historical stock prices|
|Current Share Price||€19.20|
|52 Week High||€8.25|
|52 Week Low||€24.00|
|1 Month Change||-2.04%|
|3 Month Change||41.18%|
|1 Year Change||120.69%|
|3 Year Change||45.46%|
|5 Year Change||116.70%|
|Change since IPO||-15.27%|
Recent News & Updates
These 4 Measures Indicate That Clínica Baviera (BME:CBAV) Is Using Debt Safely
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Investors Shouldn't Overlook The Favourable Returns On Capital At Clínica Baviera (BME:CBAV)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
|CBAV||ES Healthcare||ES Market|
Return vs Industry: CBAV exceeded the Spanish Healthcare industry which returned 13.7% over the past year.
Return vs Market: CBAV exceeded the Spanish Market which returned 23.8% over the past year.
Stable Share Price: CBAV is more volatile than 90% of Spanish stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CBAV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
|n/a||736||Eduardo Baviera Sabater||https://www.clinicabaviera.com|
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, vías lagrimales, and oculoplasty treatments.
Clínica Baviera Fundamentals Summary
|CBAV fundamental statistics|
Is CBAV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CBAV income statement (TTM)|
|Cost of Revenue||€78.09m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.65|
|Net Profit Margin||16.89%|
How did CBAV perform over the long term?See historical performance and comparison
2.9%Current Dividend Yield
Is Clínica Baviera undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CBAV (€19.2) is trading below our estimate of fair value (€76.85)
Significantly Below Fair Value: CBAV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CBAV is good value based on its PE Ratio (11.6x) compared to the European Healthcare industry average (23.8x).
PE vs Market: CBAV is good value based on its PE Ratio (11.6x) compared to the Spanish market (23.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBAV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBAV is overvalued based on its PB Ratio (6.1x) compared to the XE Healthcare industry average (2.3x).
How is Clínica Baviera forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Clínica Baviera has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Clínica Baviera performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBAV has high quality earnings.
Growing Profit Margin: CBAV's current net profit margins (16.9%) are higher than last year (7.8%).
Past Earnings Growth Analysis
Earnings Trend: CBAV's earnings have grown by 18% per year over the past 5 years.
Accelerating Growth: CBAV's earnings growth over the past year (209%) exceeds its 5-year average (18% per year).
Earnings vs Industry: CBAV earnings growth over the past year (209%) exceeded the Healthcare industry 40.8%.
Return on Equity
High ROE: CBAV's Return on Equity (52.6%) is considered outstanding.
How is Clínica Baviera's financial position?
Financial Position Analysis
Short Term Liabilities: CBAV's short term assets (€36.5M) exceed its short term liabilities (€34.0M).
Long Term Liabilities: CBAV's short term assets (€36.5M) do not cover its long term liabilities (€41.7M).
Debt to Equity History and Analysis
Debt Level: CBAV's debt to equity ratio (25.9%) is considered satisfactory.
Reducing Debt: CBAV's debt to equity ratio has reduced from 57.5% to 25.9% over the past 5 years.
Debt Coverage: CBAV's debt is well covered by operating cash flow (288.9%).
Interest Coverage: CBAV's interest payments on its debt are well covered by EBIT (78.8x coverage).
What is Clínica Baviera current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CBAV's dividend (2.87%) is higher than the bottom 25% of dividend payers in the Spanish market (1.5%).
High Dividend: CBAV's dividend (2.87%) is low compared to the top 25% of dividend payers in the Spanish market (5.45%).
Stability and Growth of Payments
Stable Dividend: CBAV's dividend payments have been volatile in the past 10 years.
Growing Dividend: CBAV's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (33.4%), CBAV's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Eduardo Baviera Sabater (53 yo)
Mr. Eduardo Baviera Sabater serves as the Chief Executive Officer of Clínica Baviera, S.A. and served as its Executive Chairman since February 12 2007 and also served as its Managing Director. Mr. Baviera...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Eduardo's total compensation is reasonable compared to companies of similar size in the Spanish market.
Compensation vs Earnings: Eduardo's compensation has been consistent with company performance over the past year.
Experienced Board: CBAV's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Clínica Baviera, S.A.'s employee growth, exchange listings and data sources
- Name: Clínica Baviera, S.A.
- Ticker: CBAV
- Exchange: BME
- Founded: NaN
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: €313.026m
- Shares outstanding: 16.30m
- Website: https://www.clinicabaviera.com
Number of Employees
- Clínica Baviera, S.A.
- Paseo de la Castellana 20
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/23 17:46|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.